Ethical and economic issues in the appraisal of medicines for ultra-rare conditions In the light of concerns around the suitability of the National Institute for Health and Care Excellence's Highly Specialised Technologies (HST) appraisal route, this report discusses the distinct ethical and economic challenges faced by ultra-orphan medicines, with particular reference to the challenges of health technology assessment in the UK. Office of Health Economics
No comments:
Post a Comment